Tirzepatide

CAS No.: 2023788-19-2

Tirzepatide Chemical Structure

Molecular formula : C₂₂₅H₃₄₈N₄₈O₆₈
Molecular weight : 4813.45
Dositive specifications : 2. 5mg, 5mg, 7. 5mg, 10mg, 15mg/0. 5ml
Injection : 2. 5 mg, 5 mg, 7. 5 mg, 10 mg, 12. 5 mg, or 15 mg / 0. 5 mL in single-dose pen

Get in touch Download

Products are for laboratory research use only. Not for human use. We do not sell to patients.

Biological Activity

Terzapitide Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) , in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined .

MOUNJARO

Chemical Properties

ACTIONS	—
CAS NO.	2023788-19-2
FORMULA	C225H348N48O68
M.WT	4813.45
PURITY	98％
SYNONYMS	GIPGLP-1
STORAGE	—

Online Inquiry

Diabetes

Chinese diabetic people may have a total of 143 million people, accounting for 23%of the global patients with diabetes. It is the country with the most diabetic patients in the world. Among them, type II diabetes account for about 90%of the number of diabetes, and type I diabetes and gestational diabetes account for about 9 ~ 10%.

Other Drug Peptide More+

Semaglutide new

Semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) , in humans as the human relevance of semaglutide-induced rodent thyroid Ccell tumors has not been determined.
Tirzepatide new

Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) , in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined .
Retatrutide new

Retarutide (LY3437943) is a triple agonist peptide of glucagon receptor (GCGR) , glucose-dependent insulin-promoting peptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R) . It is a peptide composed of about 40 amino acids and contains double targets in its sequence. Retarutide inhibited human GCGR, GIPR and GLP-1R with EC50 values of 5. 79, 0. 0643 and 0. 775nM, respectively. Retarutide can be used for obesity research.
Cagrilintide new

Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity.

Product Catalog

Tirzepatide

GUIZHOU MTPEPTIDES BIOTECHNOLOGY CO., LTD